A list of commonly used measurement tools for psoriasis management and clinical trials.
The DermSat-7 is a patient-reported outcome measure designed to assess patient satisfaction with psoriasis treatment. It consists of seven key questions evaluating treatment effectiveness, convenience, and overall satisfaction, providing valuable insights for both patients and healthcare providers.
A simple 10-question validated questionnaire that has been used for more than 40 different skin conditions in over 80 countries and is available in over 110 languages to measure disease severity and quality of life.
A simple proxy for PASI and DLQI using body surface area (BSA) and one or more of Skin Pain Visual Analog Score (Skin Pain VAS), Itch numeric rating scale (Itch NRS), and patient global assessment (patGA).
Quantifies the severity of psoriasis measured by redness, thickness, and scaliness of the lesions, weighed by the area of involvement.
Physician’s assessment of the severity of disease based on a scale from clear to very severe.
Self-administered, patient-reported outcome measure (PRO) to assess symptom severity in chronic plaque psoriasis.
The Simplified Psoriasis Index (SPI) is a tool that has been developed to enable either healthcare professionals or patients with psoriasis to make regular assessments of disease severity and its impact on well-being. It also incorporates a summary of past behavior and treatment.
A 10-question questionnaire based on the experiences of children with skin disease. Available in both a text-only version and the Cartoon CDLQI, with each question illustrated by a cartoon based on the theme of the question, catering to younger children.
GET THE CDLQI
DOWNLOAD THE OFFICIAL APP (free) – Apple
DOWNLOAD THE OFFICIAL APP (free) – Google Play
A clinical tool used to assess the severity of nail psoriasis, focusing on specific features of nail involvement.
A clinical tool for evaluating the severity of psoriasis on the hands and feet. Based on erythema, scaling, and pustule presence, the PPPGA ranges from clear to severe.
A validated screening tool for psoriatic arthritis (PsA). It is recommended that patients with psoriasis who do not have a diagnosis of PsA complete an annual PEST questionnaire (NICE psoriasis guidelines 2012). A score of 3 or more indicates referral to rheumatology should be considered.
A clinical assessment tool used to measure the severity of psoriasis specifically on the scalp, based on erythema, scaling, and thickness.
A clinical outcome measure for the assessment of genital psoriasis severity that accounts for the erythematous clinical presentation of genital psoriasis.
A validated online measure designed to comprehensively evaluate disease activity in generalized pustular psoriasis, providing clinicians with a reliable tool to assess the severity and progression of the condition.
Includes validated tools that help clinicians accurately monitor disease severity, progression, and treatment response.
This confirms the reliability and accuracy in assessing disease severity and extent, providing essential tools for clinicians to effectively evaluate and manage generalized pustular psoriasis.
IPC does not endorse or accept any responsibility for the content of external websites.
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.
